Chemoradiotherapy
Johnson & Johnson’s Bladder Cancer Treatment Falls Short Against Chemoradiation
Johnson & Johnson, bladder cancer, chemoradiation, TAR-200, SunRISe-1 study
KEYTRUDA (Pembrolizumab) Plus Chemoradiotherapy Reduces Mortality Risk by 33% in High-Risk Locally Advanced Cervical Cancer
KEYTRUDA (pembrolizumab), Chemoradiotherapy (CRT), High-risk locally advanced cervical cancer, Overall survival (OS), European Society for Medical Oncology (ESMO) Congress 2024